4.4 Article

Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines

Journal

PROSTATE
Volume 60, Issue 3, Pages 175-177

Publisher

WILEY
DOI: 10.1002/pros.20116

Keywords

prostate cancer; atrasentan; endothelin-1; PSA; endothelin receptor

Ask authors/readers for more resources

BACKGROUND. Some men treated with atrasentan (ABT-627), an endothelin A (ETA) receptor inhibitor, had declines in their serum PSA levels. It is our hypothesis that this decrease is due to anti-tumoral activity and not a reduction in PSA secretion at the cellular level. METHODS. Two PSA secreting prostate cancer cell lines (LAPC4 and LNCaP) were treated with atrasentan and an ETB receptor antagonist (A192621) in varying concentrations (10(-6)-10(-10) M) and PSA levels were measured in the culture media. RESULTS. LNCaP and LAPC4 cells both express ETA receptors. Neither the ETA or ETB antagonist altered PSA secretion, while addition of DHT, a positive control, produced a marked increase in PSA secretion. CONCLUSIONS. Blockade of the ETA receptor does not affect the secretion of PSA in prostate cancer cell lines. (C) 2004 Wiley-Liss, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available